Pediatric posterior fossa incidentalomas.
Brain tumor
Incidentalomas
Pediatric
Posterior fossa tumor
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
12
06
2019
accepted:
30
08
2019
pubmed:
8
9
2019
medline:
22
6
2021
entrez:
8
9
2019
Statut:
ppublish
Résumé
Pediatric brain incidentalomas are increasingly being diagnosed. As the posterior fossa (PF) is the location of most brain tumors in children, lesions of this region are of special interest. Currently, the natural history of incidental lesions in the PF is unknown. We present our experience treating such lesions. A retrospective study was carried out in two large tertiary pediatric centers. Patients were included if they had an incidental PF lesion suspected of being a tumor, and diagnosed before the age of 20 years. We analyzed treatment strategy, pathology, and outcome of operated and non-operated cases. Seventy children (31 females) with a mean age of 8.4 ± 6.1 years were included. The three most common indications for imaging were headaches (16, assumed to be unrelated to the lesions), workup of unrelated conditions (14), and unspecified reasons (14). Twenty-seven patients (39%) were operated immediately, and 43 followed, of which 12 were eventually operated due to radiological changes, 28.9 ± 16.2 months after diagnosis. The most commonly found pathology was pilocytic astrocytomas (21 of 39 operated cases). Almost 10% were found to be malignant tumors including medulloblastomas (5) and ATRT (1). Incidental PF lesions in children include both benign and malignant tumors. While certain lesions may be followed, others may require surgical treatment. Specific treatment decisions are based on initial radiological appearance, change in radiological characteristics over time, location, and evolving symptoms. The surgical risks must be balanced vis-à-vis the risk of missing a high-grade tumor and the very rare risk of malignant transformation.
Identifiants
pubmed: 31492982
doi: 10.1007/s00381-019-04364-0
pii: 10.1007/s00381-019-04364-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-609Références
Acta Neurochir (Wien). 2014 Feb;156(2):375-81
pubmed: 24272523
Nat Genet. 2013 Jun;45(6):602-12
pubmed: 23583981
Childs Nerv Syst. 2016 Dec;32(12):2433-2438
pubmed: 27392443
J Neurosurg Pediatr. 2012 Sep;10(3):168-74
pubmed: 22816603
Acta Neurochir (Wien). 2011 Mar;153(3):473-7
pubmed: 21191802
J Clin Oncol. 2015 Mar 20;33(9):1015-22
pubmed: 25667294
Neurosurg Focus. 2011 Dec;31(6):E20
pubmed: 22133179
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28708330
MAGMA. 2009 Feb;22(1):5-18
pubmed: 18989714
AJNR Am J Neuroradiol. 2011 Oct;32(9):1570-7
pubmed: 21051510
Neuro Oncol. 2017 Jun 1;19(6):741-743
pubmed: 28379448
Nat Genet. 2013 Aug;45(8):927-32
pubmed: 23817572
Pediatrics. 2015 Apr;135(4):e1084-96
pubmed: 25825535
World Neurosurg. 2014 Feb;81(2):368-73
pubmed: 23321383
Lancet Oncol. 2007 Aug;8(8):685-95
pubmed: 17644483
Pediatrics. 2013 Aug;132(2):e356-63
pubmed: 23878053
BMJ. 2009 Aug 17;339:b3016
pubmed: 19687093
NMR Biomed. 2006 Jun;19(4):411-34
pubmed: 16763971
J Neurooncol. 2012 Feb;106(3):589-94
pubmed: 21853423
J Clin Oncol. 2007 Feb 20;25(6):682-9
pubmed: 17308273
J Neurosurg Pediatr. 2010 May;5(5):479-85
pubmed: 20433262
NMR Biomed. 2012 Apr;25(4):661-73
pubmed: 21954036
Eur J Cancer. 2013 Feb;49(3):658-67
pubmed: 23036849
Childs Nerv Syst. 2017 Dec;33(12):2169-2175
pubmed: 28808787
Cancer. 1996 Jan 15;77(2):362-72
pubmed: 8625246
N Engl J Med. 2017 Oct 19;377(16):1593-1595
pubmed: 29045203
Childs Nerv Syst. 2018 Jul;34(7):1325-1333
pubmed: 29802595
J Neurosurg. 2012 Feb;116(2):365-72
pubmed: 21999317